Accéder au contenu
Merck

Fluorescent Trimethoprim Conjugate Probes To Assess Drug Accumulation in Wild Type and Mutant Escherichia coli.

ACS infectious diseases (2016-10-16)
Wanida Phetsang, Ruby Pelingon, Mark S Butler, Sanjaya Kc, Miranda E Pitt, Geraldine Kaeslin, Matthew A Cooper, Mark A T Blaskovich
RÉSUMÉ

Reduced susceptibility to antimicrobials in Gram-negative bacteria may result from multiple resistance mechanisms, including increased efflux pump activity or reduced porin protein expression. Up-regulation of the efflux pump system is closely associated with multidrug resistance (MDR). To help investigate the role of efflux pumps on compound accumulation, a fluorescence-based assay was developed using fluorescent derivatives of trimethoprim (TMP), a broad-spectrum synthetic antibiotic that inhibits an intracellular target, dihydrofolate reductase (DHFR). Novel fluorescent TMP probes inhibited eDHFR activity with comparable potency to TMP, but did not kill or inhibit growth of wild type Escherichia coli. However, bactericidal activity was observed against an efflux pump deficient E. coli mutant strain (ΔtolC). A simple and quick fluorescence assay was developed to measure cellular accumulation of the TMP probe using either fluorescence spectroscopy or flow cytometry, with validation by LC-MS/MS. This fluorescence assay may provide a simple method to assess efflux pump activity with standard laboratory equipment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Dihydrofolate Reductase Assay Kit, 1 kit sufficient for 50-100 tests